DexCom’s second quarter was marked by robust revenue growth and a significant margin expansion, with management attributing performance to strong global demand for its continuous glucose monitoring (CGM) solutions and broadening patient access. CEO Jake Leach cited “solid execution across the business,” including multiple product launches and continued share gains in core markets. International momentum, particularly in markets where reimbursement recently expanded, also played a key role. Operational improvements, such as manufacturing efficiencies and a successful rollout of the G7 15-day system, further contributed to the company’s margin gains and customer satisfaction.
Is now the time to buy DXCM? Find out in our full research report (it’s free for active Edge members).
DexCom (DXCM) Q2 CY2026 Highlights:
- Revenue: $1.31 billion vs analyst estimates of $1.29 billion (13.1% year-on-year growth, 1.4% beat)
- Adjusted EPS: $0.70 vs analyst estimates of $0.61 (15.1% beat)
- Adjusted EBITDA: $421.3 million vs analyst estimates of $390.7 million (32.2% margin, 7.8% beat)
- The company slightly lifted its revenue guidance for the full year to $5.22 billion at the midpoint from $5.21 billion
- Operating Margin: 24.3%, up from 18.4% in the same quarter last year
- Organic Revenue rose 12% year on year (beat)
- Market Capitalization: $31.19 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From DexCom’s Q2 Earnings Call
-
Travis Lee Steed (Bank of America) asked about sustainability of U.S. CGM growth and impact from Nutrisense. CFO Jereme Sylvain explained that robust new patient starts and untapped coverage for 9 million Americans support long-term growth, while Nutrisense revenue contribution is immaterial but enhances engagement.
-
Robert Marcus (JPMorgan) inquired about CONNECT trial reception and its potential to drive adoption among non-insulin type 2 patients. CEO Jake Leach emphasized the high engagement and improved outcomes demonstrated, noting that this strengthens the case for broad reimbursement and clinical support.
-
Matthew Taylor (Jefferies) sought updates on the timeline for CMS coverage following the CONNECT trial submission. Leach confirmed expectations for a decision by year-end, with baseline assumptions unchanged and potential for mid-2027 implementation.
-
Jayson Bedford (Raymond James) questioned the sustainability of operating expense leverage. Sylvain responded that ongoing cost discipline should continue, but near-term investments to ramp up the Ireland facility will temporarily affect margins.
-
Marie Thibault (BTIG) asked about international growth drivers and sustainability given tougher comparisons. Leach pointed to ongoing reimbursement wins and product portfolio expansion as key to maintaining momentum despite more challenging year-over-year comparisons.
Catalysts in Upcoming Quarters
In the coming quarters, our analyst team will monitor (1) the outcome of the CMS decision on coverage for type 2 diabetes patients not on insulin, (2) the pace and impact of G7 15-day system adoption in the U.S. and new international approvals, and (3) the operational ramp-up of the Ireland manufacturing facility. Additional focus will be placed on how integration of Nutrisense and digital health initiatives affect patient engagement and recurring revenue.
DexCom currently trades at $83.03, up from $74.54 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
The Best Stocks for High-Quality Investors
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
